Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Physiological State of Therapy Dogs during Animal-Assisted Activities in an Outpatient Setting
Clark, Stephanie , Martin, François , McGowan, Ragen T. S. , Smidt, Jessica M., Anderson, Rachel , Turpin, Tricia, Langenfeld-McCoy, Natalie, Bauer, Brent A. , Mohabbat, Arya B. , Clark, Stephanie D, Mohabbat, Arya B , Wang, Lei

Mayo Clinic

Animals | May 11, 2020 | Volume: 10 | Issue: 5 | Pages: 819

10.3390/ani10050819 | PMID 32397366 Get It

Therapy dogs are increasingly being incorporated into numerous clinical settings. However, there are only a handful of studies that have focused on the impact of animal-assisted activity or therapy sessions on the wellbeing of the therapy dogs. Furthermore, these studies show mixed results. The goal of this study was to provide an in-depth picture of the effects of these interactions on the dogs involved by considering multiple physiological measures known to be associated with emotional state (continuous heart rate, heart rate variability, pre- and post-session tympanic membrane temperatures, and salivary cortisol and oxytocin concentrations). Nineteen Mayo Clinic Caring Canine therapy dogs completed five 20-minute animal-assisted activity (AAA) visits each in an outpatient clinical setting (Mayo Clinic Fibromyalgia and Chronic Fatigue Clinic). From a physiological perspective, the dogs showed a neutral to positive response to the AAA sessions. Heart rate (HR) was significantly lower at the end of the session compared with the beginning of the session (F = 17.26, df1 = 1, df2 = 29.7, p = 0.0003). The right tympanic membrane temperature was lower post-session (F = 8.87, df1 = 1, df2 = 107, p = 0.003). All other emotional indicators remained stable between pre- and post-session. These results suggest that the dogs involved were not negatively affected by their participation in the AAA. Moreover, there was some evidence suggesting the dogs may have been in a more relaxed state at the end of the session (lower HR and lower right tympanic membrane temperature) compared to the beginning of the session.
Effect of Ketamine/Propofol Admixture on Peri-Induction Hemodynamics: A Systematic Review and Meta-Analysis
Smischney, Nathan J. , Seisa, Mohamed O. , Morrow, Allison S. , Ponce, Oscar J. , Alzuabi, Muayad , Heise, Katherine J., Murad, M. Hassan , Murad, Mohammad H, Murad, M Hassan , Smischney, Nathan J , Ponce, Oscar Josue , Wang, Zhen

Mayo Clinic

Anesthesiology Research and Practice | May 8, 2020 | Volume: 2020 | Issue: No issue available | Pages: 1-15

10.1155/2020/9637412 | PMID 32454816 Get It

To evaluate the effectiveness of an admixture of ketamine and propofol on peri-induction hemodynamics during airway manipulation, we searched electronic databases of randomized controlled trials from January 1, 2000, to October 17, 2018. Trial screening, selection, and data extraction were done independently by two reviewers with outcomes pooled across included trials using the random-effects model. We included 10 randomized trials (722 patients, mean age of 53.99 years, 39.96% female). American Society of Anesthesiologists physical status was reported in 9 trials with classes I and II representing the majority. Ketamine/propofol admixture was associated with a nonsignificant increase in heart rate (weighted mean difference, 3.36 beats per minute (95% CI, −0.88, 7.60), I2 = 88.6%), a statistically significant increase in systolic blood pressure (weighted mean difference, 9.67 mmHg (95% CI, 1.48, 17.86), I2 = 87.2%), a nonsignificant increase in diastolic blood pressure (weighted mean difference, 2.18 mmHg (95% CI, −2.82, 7.19), I2 = 73.1%), and a nonsignificant increase in mean arterial pressure (weighted mean difference, 3.28 mmHg (95% CI, −0.94, 7.49), I2 = 69.9%) compared to other agents. The risk of bias was high and the certainty of evidence was low. In conclusion, among patients undergoing airway manipulation and needing sedation, the use of a ketamine/propofol admixture may be associated with better hemodynamics compared to nonketamine/propofol sedation. This trial is registered with CRD42019125725.
SUN-672 SGLT2 Inhibitor Reduces Hyperinsulinemia and Restores Pulsatile Growth Hormone Secretion in Obese MC4RKO Mice
Wang, Chengjian , Zhu, Shanli, Qi, Xinzhou , Chen, Yang , Zhang, Yanjun , Veldhuis, Johannes D. , Huang, Zhengxiang , Huang, Lili , Cowley, Michael A. , Chen, Chen

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.1158 Get It

Abstract Insulin and growth hormone (GH) are crucial counter-regulatory hormones in regulating glucose and lipid metabolisms. Insulin promotes fat storage, while GH promotes lipolysis and fat oxidation. In obese individuals, reduced GH secretion (hyposomatotropism) and increased insulin secretion (hyperinsulinemia) co-exist. The imbalance of these two hormones exacerbates fat accumulation. Therapeutic approaches to correct such hormonal imbalance in obesity are limited. The sodium/glucose cotransporter 2 inhibitor (SGLT2i), which promotes urinary glucose excretion, is a novel drug for overt type 2 diabetes (T2D). However, little is known about its efficacy in obese individuals without T2D in the clinic, in particular with hormonal imbalance. By applying SGLT2i (dapagliflozin, 1 mg/kg/d for 10 weeks) to a hyperphagic obese melanocortin 4 receptor knockout (MC4RKO) mouse model, we observed a significant reduction of hyperinsulinemia (fasting: 1.36±0.19 vs. 4.93±1.04 ng/ml, p<0.01; fed: 9.50±3.37 vs. 31.11±5.85 ng/ml, p<0.05, n=8) and restored pulsatile GH secretion without changing secretion pattern (pulsatile GH: 185.3±18.37 vs. 56.28±13.22 ng/ml per 6h, p<0.001; GH mass per secretion pulse: 50.31±8.20 vs. 15.55±3.18 ng/ml, p<0.01; number of secretory pulse per 6h: 3.71±0.29 vs. 3.57±0.43, p=0.78, n=8) as early as 4 weeks after the initiation of the treatment. Lipolysis and lipid oxidation-related gene expression levels were increased by SGLT2i treatment, whereas lipogenesis and inflammation gene expression levels were reduced, leading to decreased whole-body fat mass. Following the treatment, glucose tolerance and insulin sensitivity were both improved. Although a null effect was observed in food intake and daily activity, the treatment significantly promoted lipid usage and shifted energy metabolism towards negative energy balance. In conclusion, 10-week SGLT2i treatment improved glucose and lipid metabolisms in the hyperphagic obese MC4RKO mice. Such improvement occurs alongside reduced hyperinsulinemia and restored pulsatile GH secretion. This work provides insights for the potential use of SGLT2i in obese individuals prior to overt T2D. The final version of this work is published (1). Acknowledgements: grant (NHMRC, University of Queensland) and scholarship (CSC and UQ International scholarship) Reference: (1) Huang, Zhengxiang, et al. “Dapagliflozin restores insulin and growth hormone secretion in obese mice.” Journal of Endocrinology 245.1 (2020): 1-12. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.
Integrating Convolutional Neural Networks and Multi-Task Dictionary Learning for Cognitive Decline Prediction with Longitudinal Images
Dong, Qunxi , Zhang, Jie , Li, Qingyang , Wang, Junwen , Leporé, Natasha , Caselli, Richard J. , Ye, Jieping , Wang, Yalin , Initiative, for the Alzheimer’s Disease Neuroimaging, Wang, Junwen , Wang, Yalin , Thompson, Paul M. , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Journal of Alzheimer’s Disease | May 8, 2020 | Volume: 75 | Issue: 3 | Pages: 971-992

10.3233/jad-190973 | PMID 32390615 Get It

Background: Disease progression prediction based on neuroimaging biomarkers is vital in Alzheimer’s disease (AD) research. Convolutional neural networks (CNN) have been proved to be powerful for various computer vision research by refining reliable and high-level feature maps from image patches. Objective: A key challenge in applying CNN to neuroimaging research is the limited labeled samples with high dimensional features. Another challenge is how to improve the prediction accuracy by joint analysis of multiple data sources (i.e., multiple time points or multiple biomarkers). To address these two challenges, we propose a novel multi-task learning framework based on CNN. Methods: First, we pre-trained CNN on the ImageNet dataset and transferred the knowledge from the pre-trained model to neuroimaging representation. We used this deep model as feature extractor to generate high-level feature maps of different tasks. Then a novel unsupervised learning method, termed Multi-task Stochastic Coordinate Coding (MSCC), was proposed for learning sparse features of multi-task feature maps by using shared and individual dictionaries. Finally, Lasso regression was performed on these multi-task sparse features to predict AD progression measured by the Mini-Mental State Examination (MMSE) and the Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-Cog). Results: We applied this novel CNN-MSCC system on the Alzheimer’s Disease Neuroimaging Initiative dataset to predict future MMSE/ADAS-Cog scales. We found our method achieved superior performances compared with seven other methods. Conclusion: Our work may add new insights into data augmentation and multi-task deep model research and facilitate the adoption of deep models in neuroimaging research.
Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer
Madamsetty, Vijay Sagar , Pal, Krishnendu , Dutta, Shamit K., Wang, Enfeng , Dutta, Shamit Kumar, Pal, Krishnendu , Madamsetty, Vijay S , Mukhopadhyay, Debabrata

Mayo Clinic

Cancers | May 8, 2020 | Volume: 12 | Issue: 5 | Pages: 1189

10.3390/cancers12051189 | PMID 32397114 Get It

Despite recent advancements, effective treatment for pancreatic ductal adenocarcinoma (PDAC) has remained elusive. The overall survival rate in PDAC patients has been dismally low due to resistance to standard therapies. In fact, the failure of monotherapies to provide long-term survival benefits in patients led to ascension of several combination therapies for PDAC treatment. However, these combination therapies provided modest survival improvements while increasing treatment-related adverse side effects. Hence, recent developments in drug delivery methods hold the potential for enhancing therapeutic benefits by offering cocktail drug loading and minimizing chemotherapy-associated side effects. Nanoformulations-aided deliveries of anticancer agents have been a success in recent years. Yet, improving the tumor-targeted delivery of drugs to PDAC remains a major hurdle. In the present paper, we developed several new tumor-targeted dual intervention-oriented drug-encapsulated (DIODE) liposomes. We successfully formulated liposomes loaded with gemcitabine (G), paclitaxel (P), erlotinib (E), XL-184 (c-Met inhibitor, X), and their combinations (GP, GE, and GX) and evaluated their in vitro and in vivo efficacies. Our novel DIODE liposomal formulations improved median survival in comparison with gemcitabine-loaded liposomes or vehicle. Our findings are suggestive of the importance of the targeted delivery for combination therapies in improving pancreatic cancer treatment.
Open versus minimally invasive decompression for low-grade spondylolisthesis: analysis from the Quality Outcomes Database
Bisson, Erica F. , Mummaneni, Praveen V. , Virk, Michael S. , Knightly, John J. , Alvi, Mohammed Ali , Chan, Andrew K. , Glassman, Steven D. , Foley, Kevin T. , Slotkin, Jonathan R., Potts, Eric A. , Shaffrey, Mark E., Shaffrey, Christopher I. , Haid, Regis W., Fu, Kai-Ming, Wang, Michael Y. , Park, Paul , Asher, Anthony L. , Bydon, Mohamad , Alvi, Mohammed Ali , Goyal, Anshit , Guan, Jian

Mayo Clinic

Journal of Neurosurgery: Spine | May 8, 2020 | Volume: 33 | Issue: 3 | Pages: 349-359

10.3171/2020.3.spine191239 | PMID 32384269 Get It

OBJECTIVELumbar decompression without arthrodesis remains a potential treatment option for cases of low-grade spondylolisthesis (i.e., Meyerding grade I). Minimally invasive surgery (MIS) techniques have recently been increasingly used because of their touted benefits including lower operating time, blood loss, and length of stay. Herein, the authors analyzed patients enrolled in a national surgical registry and compared the baseline characteristics and postoperative clinical and patient-reported outcomes (PROs) between patients undergoing open versus MIS lumbar decompression.METHODSThe authors queried the Quality Outcomes Database for patients with grade I lumbar degenerative spondylolisthesis undergoing a surgical intervention between July 2014 and June 2016. Among more than 200 participating sites, the 12 with the highest enrollment of patients into the lumbar spine module came together to initiate a focused project to assess the impact of fusion on PROs in patients undergoing surgery for grade I lumbar spondylolisthesis. For the current study, only patients in this cohort from the 12 highest-enrolling sites who underwent a decompression alone were evaluated and classified as open or MIS (tubular decompression). Outcomes of interest included PROs at 2 years; perioperative outcomes such as blood loss and complications; and postoperative outcomes such as length of stay, discharge disposition, and reoperations.RESULTSA total of 140 patients undergoing decompression were selected, of whom 71 (50.7%) underwent MIS and 69 (49.3%) underwent an open decompression. On univariate analysis, the authors observed no significant differences between the 2 groups in terms of PROs at 2-year follow-up, including back pain, leg pain, Oswestry Disability Index score, EQ-5D score, and patient satisfaction. On multivariable analysis, compared to MIS, open decompression was associated with higher satisfaction (OR 7.5, 95% CI 2.41–23.2, p = 0.0005). Patients undergoing MIS decompression had a significantly shorter length of stay compared to the open group (0.68 days [SD 1.18] vs 1.83 days [SD 1.618], p < 0.001).CONCLUSIONSIn this multiinstitutional prospective study, the authors found comparable PROs as well as clinical outcomes at 2 years between groups of patients undergoing open or MIS decompression for low-grade spondylolisthesis.
PTU-055 Comparative cost-effectiveness of gastroesophageal reflux disease (GORD) centric and population based barrett’s oesophagus (BO) screening
Sami, Sarmed S. , Rosedahl, Jordan K., Katzka, David A. , Ahlquist, David A. , Moriarty, James P. , Borah, Bijan J. , Kisiel, John B. , Wang, Kenneth , Iyer, Prasad

Mayo Clinic

Posters | May 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A142.1-A142

10.1136/gutjnl-2019-bsgabstracts.268 Get It

Exome sequencing analysis identifies frequent oligogenic involvement and FLNB variants in adolescent idiopathic scoliosis
Liang, Shulun, He, Kai , Hu, Jinghua , Xu, Enjie , Lin, Tao , Zhao, Jianquan , Ma, Jun , Gao, Rui , Wang, Ce , Yang, Fu , Zhou, Xuhui , He, Kai , Jiang, Heng , Meng, Yichen

Mayo Clinic

Journal of Medical Genetics | May 7, 2020 | Volume: 57 | Issue: 6 | Pages: 405-413

10.1136/jmedgenet-2019-106411 | PMID 32381728 Get It

Background Adolescent idiopathic scoliosis (AIS) is a genetically heterogeneous disease characterised by three-dimensional deformity of the spine in the absence of a congenital spinal anomaly or neurological musculoskeletal disorder. The clinical variability and incomplete penetrance of some genes linked with AIS indicate that this disease constitutes an oligogenic trait. Objective We aimed to explore the oligogenic nature of this disease and identify novel AIS genes. Methods We analysed rare damaging variants within AIS-associated genes by using exome sequencing in 40 AIS trios and 183 sporadic patients. Results Multiple variants within AIS-associated genes were identified in eight AIS trios, and five individuals harboured rare damaging variants in the FLNB gene. The patients showed more frequent oligogenicity than the controls. In the gene-based burden test, the top signal resided in FLNB . In functional studies, we found that the AIS-associated FLNB variants altered the protein’s conformation and subcellular localisation and its interaction with other proteins (TTC26 and OFD1) involved in AIS. The most compelling evidence of an oligogenic basis was that the number of rare damaging variants was recognised as an independent prognostic factor for curve progression in Cox regression analysis. Conclusion Our data indicate that AIS is an oligogenic disease and identify FLNB as a susceptibility gene for AIS.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Holtan, Shernan G. , Wang, Tao , Hemmer, Michael, Arora, Mukta , Couriel, Daniel R. , Pidala, Joseph, Abdel‐Azim, Hisham , Ahmed, Ibrahim , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Antin, Joseph H. , Askar, Medhat , Auletta, Jeffery J. , Daly, Andrew , DeFilipp, Zachariah , Gajewski, James , Hematti, Peiman , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Martino, Rodrigo , Majhail, Navneet S. , Marks, David I. , Pawarode, Attaphol , Prestidge, Tim , Rangarajan, Hemalatha G. , Ringdén, Olle , Saad, Ayman , Schoemans, Hélène , Seo, Sachiko , Solh, Melhem , Spitzer, Thomas R. , Storek, Jan , Verdonck, Leo F. , Wirk, Baldeep , Cahn, Jean‐Yves , Weisdorf, Daniel J. , Saad, Ayman , Ringden, Olov , Weisdorf, Dan , Majhail, Navneet S , Martino, Rodrigo , Holtan, Shernan , Auletta, Jeffery J , Hematti, Peiman , Mehta, Rohtesh S. , Spellman, Stephen R. , Alousi, Amin Majid , Agrawal, Vaibhav , Bhatt, Vijaya Raj , Chee, Lynette Chui Yen , Chhabra, Saurabh , Gale, Robert Peter , Gergis, Usama , Hogan, William J. , Nishihori, Taiga , Olsson, Richard F. , Díaz, Miguel Ángel , Savani, Bipin N. , Schultz, Kirk R. , Teshima, Takanori , Yared, Jean A.

Mayo Clinic

Journal of Clinical Oncology | May 4, 2020 | Volume: 38 | Issue: 18 | Pages: 2062-2076

10.1200/jco.19.00396 | PMID 32364845 Get It

PURPOSE There is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]–bone marrow [BM], or 7/8-peripheral blood [PB]) for hematopoietic cell transplantation (HCT) for patients lacking an HLA-matched related or unrelated donor. METHODS We report composite end points of graft-versus-host disease (GVHD)–free relapse-free survival (GRFS) and chronic GVHD (cGVHD)–free relapse-free survival (CRFS) in 2,198 patients who underwent UCB (n = 838), haploidentical (n = 159), 7/8-BM (n = 241), or 7/8-PB (n = 960) HCT. All groups were divided by myeloablative conditioning (MAC) intensity or reduced intensity conditioning (RIC), except haploidentical group in which most received RIC. To account for multiple testing, P < .0071 in multivariable analysis and P < .00025 in direct pairwise comparisons were considered statistically significant. RESULTS In multivariable analysis, haploidentical group had the best GRFS, CRFS, and overall survival (OS). In the direct pairwise comparison of other groups, among those who received MAC, there was no difference in GRFS or CRFS among UCB, 7/8-BM, and 7/8-PB with serotherapy (alemtuzumab or antithymocyte globulin) groups. In contrast, the 7/8-PB without serotherapy group had significantly inferior GRFS, higher cGVHD, and a trend toward worse CRFS (hazard ratio [HR], 1.38; 95% CI, 1.13 to 1.69; P = .002) than the 7/8-BM group and higher cGVHD and trend toward inferior CRFS (HR, 1.36; 95% CI, 1.14 to 1.63; P = .0006) than the UCB group. Among patients with RIC, all groups had significantly inferior GRFS and CRFS compared with the haploidentical group. CONCLUSION Recognizing the limitations of a registry retrospective analysis and the possibility of center selection bias in choosing donors, our data support the use of UCB, 7/8-BM, or 7/8-PB (with serotherapy) grafts for patients undergoing MAC HCT and haploidentical grafts for patients undergoing RIC HCT. The haploidentical group had the best GRFS, CRFS, and OS of all groups.